MEK Inhibitor-Based Combination Strategies in Selected Molecular Subsets of Non-Small Cell Lung Cancer (NSCLC): rationale for the Design of Phase I Clinical Trials
The data associated with this publication are not available for this reason: NA
Abstract
Lung cancer is the leading cause of both cancer and cancer-related mortality in the United States. Targeting different receptor tyrosine kinase pathways has proven to be a potent therapeutic strategy for such cancers.
